No profile data available.
Gilead Sciences, Inc. (GILD) is a healthcare company in the antiviral pharmaceuticals industry, based in Foster City, United States, with about 17,000 full-time employees.
It reported revenue of $29.44 billion for fiscal year 2025, up 2.4% from fiscal year 2024, and net income of $8.51 billion. In Q2 2026 (the quarter ended June 30, 2026) revenue was $7.80 billion, up 10.2% from a year before. United States was its largest region in fiscal year 2025, with 71% of revenue. Its market capitalization was $187.44 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients.
Gilead Sciences reported $29.44 billion in revenue for fiscal year 2025, up 2.4% from $28.75 billion in fiscal year 2024. In Q2 2026 revenue was $7.80 billion.
United States: 71% of revenue by region in fiscal year 2025, followed by Europe (17%).
$187.44 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (antiviral pharmaceuticals) include Moderna, Inc. (MRNA), BioNTech SE (BNTX), Novavax, Inc. (NVAX), Vir Biotechnology, Inc. (VIR).